Background: In the first 2 years of grass tablet sublingual immunotherapy treat-
| INTRODUCTION
When used as a tolerance-inducing treatment for allergic diseases, allergy immunotherapy (AIT) acts through several mechanisms, including the generation of B and T regulatory responses.
1,2 AIT often induces a transient increase in specific
IgE and promotes synthesis of allergen-specific IgG antibodies, which can block the allergen-IgE interaction. This blockade consequently interferes with the IgE-mediated allergic inflammation cascade, the IgE-facilitated allergen presentation to T cells, and with the increased IgE production during high allergen exposure. [3] [4] [5] Induction of allergen-specific IgG accompanies the clinical benefits of AIT, with allergen specificity determining antibody ability to block allergen-dependent IgE activity. 6, 7 Regulatory T cells are also decisive for the suppression of allergic inflammation and long-term tolerance. 8 Sublingual allergen immunotherapy (SLIT) has a well-established profile for safety and effectiveness in the treatment of allergic rhinitis and asthma. 9, 10 In a two-year longitudinal study on the systemic effects of SLIT, we have previously described the early and late phases of immune modulation in peripheral blood induced by a registered AIT with Phleum pratense tablets in peripheral blood samples. 11 
G R A P H I C A L A B S T R A C T
Early effect is governed by effector cell desensitization. SIgG4 interference is generated a few months after SIT initiation and is maximum in the first two treatment years. amT regulatory response is consolidated after 3 continuous treatment years and is key for sustained benefit two years after SIT cessation.
at months 1 to 4 of therapy; this was followed by a progressive downregulation orchestrated by continued production of allergen-specific antibodies other than IgE (such as sIgG 4 , and pregnancy. 12 The institutional review board approved the study protocol;
all subjects were informed of the aim of the trial and gave written consent.
All patients received daily sublingual administration of GRAZAX ® Hørsholm, Denmark (Phleum pratense, 75,000 SQ-T tablets ALK, Denmark) during the initial 3-year treatment period. Immunological evaluations were performed out of pollen season and during peak pollination (May-June).
The baseline was established in September-October 2009 before beginning AIT, as previously described. 11 During the 2-year trial extension, samples were evaluated twice yearly, in the grass pollen season (GPS) and 3 months later. Only data from the patients completing the study are included in the current report, and values from first-year therapy are reproduced when needed for comparison. (rat IgG1; eBiosciences).
Cells were surface-stained according to the manufacturer's protocols, and subset phenotype analysis was determined as previously described. Figure 1C ). sIgE/ sIgG 4 ratios at the end of trial were lower than preimmunotherapy ratios in 70% (n=21) of patients ( Figure 1D ). FAB remained lower than preimmunotherapy in 83% of patients (n=25) (Figure 2A ).
Inverse correlation was found between the sIgG 4 increase and the change from baseline in IgE-FAB at the end of therapy and afterward ( Figure 2B ).
| Acquisition of regulatory response by the end of the trial is associated with sustained reduced sIgE and GPS-eosinophil counts
The increase in circulating IL-4 + cells during the initial 1-to 4-month therapy period was followed by a significant decrease in these cells during treatment ( Figure 3A) . At the end of active therapy, circulating IL-4 + cell levels were lower than at time 0 in 89% of patients. This reduction remained at year 4 and 5 in 80% (n 24) of patients. We detected a decrease in circulating IL-4 + cells during the pollen seasons after therapy cessation, which was more pronounced in GPSIV, but not statistically significant when compared to the end of treatment ( Figure 3A ).
Peripheral eosinophil counts during GPS were used as an indicator of patient allergic response to environmental pollen. A significant reduction in number of eosinophils was detected at GPSIII vs GPSI;
this reduction was sustained in GPSIV and V post-therapy (Figure 3B) . In addition, a significant increase in the rate of the CD4 + T-cell subset with the amTreg phenotype was detected after 2 years of treatment and thereafter; this amTreg subset was generated in 63% of patients by the end of the second year of therapy 11 and persisted above 60% both throughout therapy and for the 2 years of follow-up ( Figure 3C ).
By comparing variables we found, in 40% of patients, a significant coincidence of sustained increase in the amTreg-like cell pool with the presence of end-of-trial sIgE levels lower than those at preimmunotherapy; meanwhile, 33% of the population showed neither increase in the amTreg pool nor end-of-trial reduced sIgE levels, and 23% of patients with induction in the amTreg-like cell pool showed post-therapy increase in sIgE values ( Figure 3D ). Eosinophil counts lower during GPS than in the first year of therapy were also Subjective clinical evaluation during a postseasonal visit was based on comparison between the most recent grass season and the previous one. A numerical value was assigned to all questions, ranging from −2 and −1 (degree in worsening in symptoms), 0 (no change), to 1 and 2 (degree of improvement). Cumulative values from year 1 + 2 + 3 assessment yield the end-of-therapy clinical index. Cumulative values from year 4 + 5 assessment yield post-therapy clinical index ranging from −4 to −1 (degree in worsening in symptoms both or only 1 year), 0 (no changes), to 1 to 4 (degree in improvement in symptoms both or only 1 year). showed post-therapy increase in sIgE values ( Figure 3F and Table 1 ).
| Differential patterns of response in individual patients
Patients displayed a great diversity of immunological responses, both in strength and in time of onset. As an example, sIgE, sIgG 4 We can thus analyze short-term therapy effect (first year), effects of long-term treatment (3 years) and sustained effect (5 years). The understanding of these mechanisms will be critical for the design of better specific AIT intervention strategies and for a rational use of existing therapy products.
| Short-term effect (first year)
There is a clear increase in both sIgE and circulating IL-4 + cells during the first 4 months of therapy, which is followed by a progressive decrease later on ( Figure 1A ). Levels of sIgE will be lower than baseline values only after 3 years of therapy. sIgG4 responses will be developed after 4 months of therapy. FAB inhibition shows, in parallel, a slight worsening during the first month, 14 Moreover, it has been documented that relatively high antigen doses are needed to induce clinical effect in both subcutaneous and sublingual therapy approaches. 17 These high doses may be needed for effector cell modulation. In the same way, accelerated schedules in hymenoptera venom AIT induce immunological tolerance in a few days. 18 Making effector cells unresponsive might also have a critical | 357 effect for subsequent immunological changes by shutting down key pro-inflammatory cascades. Increases in blocking antibodies were detected after 3 months of treatment in a previous study, 19 so this element may also contribute to the effect of AIT during the first treatment year. Interestingly, in a recent publication on the GRA-ZAX ® asthma prevention study 13 , grass pollen allergic children treated with the same registered product GRAZAX ® were assessed for asthma symptoms both during summer and out of season (winter),
where the latter could be related to general airway inflammation. An effect on these out-of-season asthma symptoms was observed in the third winter season and especially in follow-up seasons, indicating that peripheral improvement of general airway inflammation coincides with the onset of a regulatory response.
| Effect of long-term treatment (3 years)
In our previous publication, 11 we found that it took 2 years of con- response is generated in an earlier phase due to perennial allergen exposure. In fact, recent publications on sublingual immunotherapy in LTP-mediated food allergy, 23, 24 suggest that a T regulatory response (PD-L1+/IL-10+Treg) might be generated earlier.
| Sustained effect (2 years after cessation)
The results provided by this study demonstrate end-of-trial sIgE levels lower than those at preimmunotherapy. In fact, by comparing readouts in those patients, we have found an association of this result with both a significant increase in amTreg and a decrease in eosinophil counts at the end of the trial. Moreover, this sustained reduction in sIgE levels is also associated with clinical improvement.
In general, the amTreg cell population is maintained during the follow-up period even though some variation is observed for individual patients, suggesting that both reduction in sIgE and increased amTreg numbers should be further investigated as markers of sustained AIT effect.
| CONCLUDIN G REMARKS
Our data provide evidence that simple at-hand biomarkers, such as sustained reduction in sIgE or in GPS-associated eosinophil counts, are connected to the generation of an amTreg-like population during SLIT therapy, which in turn is related to clinical improvement. To our knowledge, we have conducted the first five-year prospective study exploring various immunological mechanisms associated with sustained effect of specific SLIT allergy intervention. We decided to maximize the chance of understanding immunological changes by allocating all patients to the active group. This was possible because the product used is documented as safe and clinically effective in multiple previous prospective and well-controlled studies for up to 5 years. 9, 10, 13 We formulated the hypothesis that the maintenance of the amTreg response after discontinuation should play a pivotal clinical role. Considering the data from the five-year study period, we can conclude that about In Figure 5 , a summary of the sequential mechanisms involved for patients attending our study is shown. It should be stressed that the mechanism suggested is based on detailed investigations of various immunological parameters in the current study. The tested product presents a good balance between safety and efficacy during continuous treatment for up to 3 years. 9, 10, 13 Thus, these findings are only applicable to this product (grass extract freeze-dried fastdissolving tablet formulation) and grass allergic patients and are not applicable to other products or different allergic disease conditions.
The diversity of immunological mechanisms involved, with different dose/effect, unique pharmacologic profile, and a different bioavailability, 25 makes extrapolation impossible and supports the need for performing independent investigations of the immunological mechanism for different immunotherapy products. 
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